Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. New Morningstar Analyst Report for E.I. du Pont de Nemours & Company

      Stock Reports

      Thu, 17 Apr 2014

      retained the patents for hypertension drugs Cozaar and Hyzaar following the sale of its pharmaceutical business to Bristol - Myers Squibb and contracted the manufacturing and marketing rights with Merck. At its peak, the pharmaceutical business contributed

    2. Smead Capital Management Shareholder Letter 1Q 2014

      Headlines

      Wed, 16 Apr 2014

      bordering on sloth—Warren Buffett). Our slight changes included selling the last of Mylan and the last of Bristol - Myers Squibb . We also trimmed Walgreens and Disney. Fast-growing small bio techs and improvement in under-valued pharmaceutical

    3. Bristol - Myers files for HIV-1 combo drug

      Headlines

      Mon, 14 Apr 2014

      Bristol - Myers Squibb ( BMY ) submits its NDA for a fixed-dose combination of the protease inhibitor Reyataz (atazanavir sulfate) and the investigational

    4. New Morningstar Analyst Report for Biogen Idec Inc

      Stock Reports

      Fri, 11 Apr 2014

      and Steve Holtzman is head of corporate development (previously at Millennium and Infinity). Bruce Ross, a Bristol - Myers Squibb veteran, retired from the board in June 2010; longtime director William Young has taken over his role as independent

    5. Bristol-Myers Squibb HCV combo succeeds in Phase III trial

      Headlines

      Thu, 10 Apr 2014

      Bristol - Myers Squibb 's ( BMY ) combination oral therapy of Daclatasvir and Asunaprevir cleared Hepatitis C in 90% of previously untreated patients in a Phase

    6. Merck Hepatitis C combo pill impresses in Phase II

      Headlines

      Thu, 10 Apr 2014

      put Merck on course to compete with Gilead ( GILD ) - whose Sovaldi is already approved - AbbVie ( ABBV ) and Bristol - Myers Squibb ( BMY ), which are also developing Hepatitis C drugs Merck shares are +1.3% premarket. Post your comment!

    7. Bristol - Myers hepatitis C treatment cures up to 90 pct -study

      Headlines

      Thu, 10 Apr 2014

      April 10 (Reuters) - A combination of two anti-viral drugs developed by Bristol - Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy

    8. Express Scripts Trying To Shame Gilead Into Reducing Sovaldi Price: Who Is Really The Greedy One?

      Headlines

      Wed, 9 Apr 2014

      designation, and treats the most frequent genotype 1 strain. Although others such as Abbvie ( ABBV ), Merck ( MRK ), and Bristol Meyers Squibb ( BMY ) are working on their own hepatitis C treatments, there is little argument among analysts that Gilead's treatment is superior

    9. Bristol - Myers submits NDAs for Hep C drugs

      Headlines

      Mon, 7 Apr 2014

      Bristol - Myers Squibb ( BMY +0.2% ) submits new drug applications to the FDA for its NS5A replication complex inhibitor daclatasvir (DVC) and its NS3

    10. How MannKind Shows Depth Of The Diabetes Market

      Headlines

      Thu, 3 Apr 2014

      diabetics. Those include GlaxoSmithKline (NYSE: GSK ) and Bristol -Meyers Squibb (NYSE: BMY , with GlaxoSmithKline have a diabetic drug on tap for FDA approval this month and Bristol -Meyers recently having one approved. GlaxoSmithKline has

    « Prev12345Next »
    Content Partners